Xencor, Inc. (XNCR)
NASDAQ: XNCR · IEX Real-Time Price · USD
23.63
-0.30 (-1.25%)
At close: May 2, 2024, 4:00 PM
23.89
+0.26 (1.10%)
Pre-market: May 3, 2024, 8:46 AM EDT
Xencor Revenue
In the year 2023, Xencor had annual revenue of $168.34M with 2.28% growth. Revenue in the quarter ending December 31, 2023 was $44.69M with 106.80% year-over-year growth.
Revenue (ttm)
$168.34M
Revenue Growth
+2.28%
P/S Ratio
8.65
Revenue / Employee
$601,207
Employees
280
Market Cap
1.46B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 168.34M | 3.76M | 2.28% |
Dec 31, 2022 | 164.58M | -110.53M | -40.18% |
Dec 31, 2021 | 275.11M | 152.42M | 124.23% |
Dec 31, 2020 | 122.69M | -34.01M | -21.70% |
Dec 31, 2019 | 156.70M | 116.10M | 285.93% |
Dec 31, 2018 | 40.60M | -5.55M | -12.02% |
Dec 31, 2017 | 46.15M | -62.87M | -57.67% |
Dec 31, 2016 | 109.02M | 81.26M | 292.70% |
Dec 31, 2015 | 27.76M | 18.24M | 191.62% |
Dec 31, 2014 | 9.52M | -652.00K | -6.41% |
Dec 31, 2013 | 10.17M | 648.00K | 6.80% |
Dec 31, 2012 | 9.52M | 2.68M | 39.06% |
Dec 31, 2011 | 6.85M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AdaptHealth | 3.20B |
Brookdale Senior Living | 3.02B |
Omnicell | 1.15B |
Pacira BioSciences | 674.98M |
NovoCure | 509.34M |
Kiniksa Pharmaceuticals | 301.77M |
Gyre Therapeutics | 113.45M |
4D Molecular Therapeutics | 20.72M |
XNCR News
- 24 days ago - Xencor Appoints Bart Cornelissen as Chief Financial Officer - Business Wire
- 2 months ago - Xencor to Present at Upcoming Investor Conferences - Business Wire
- 2 months ago - Xencor Reports Fourth Quarter and Full Year 2023 Financial Results - Business Wire
- 2 months ago - Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update - Business Wire
- 4 months ago - Xencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference - Business Wire
- 4 months ago - Dane Leone Joins Xencor as Senior Vice President, Corporate Strategy - Business Wire
- 4 months ago - 20 favorite small-cap stocks for 2024 among Wall Street analysts - Market Watch
- 5 months ago - Xencor to Present at the Piper Sandler 35th Annual Healthcare Conference - Business Wire